Patents by Inventor Congxin Liang

Congxin Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • mTOR selective kinase inhibitors
    Patent number: 8912178
    Abstract: The 4-urea-phenyl substituted 6-morpholin-4-yl-pyrazolo[3,4-d]pyrimidine derivatives are potent and selective inhibitors of mTOR kinase and are useful in treating disorders related to abnormal mTOR activities such as cancer, immune disorders, cardiovascular disease, ocular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: December 16, 2014
    Assignee: Xcovery Holdings Company, LLC
    Inventor: Congxin Liang
  • SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS
    Publication number: 20140221376
    Abstract: Pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
    Type: Application
    Filed: April 9, 2014
    Publication date: August 7, 2014
    Applicant: Xcovery Holding Company, LLC
    Inventors: Congxin Liang, Zhigang Li
  • Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
    Patent number: 8697866
    Abstract: Pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: April 15, 2014
    Assignee: Xcovery Holding Company LLC
    Inventors: Congxin Liang, Zhigang Li
  • PI3K (delta) SELECTIVE INHIBITORS
    Publication number: 20140051699
    Abstract: Novel PI3K, especially PI3K delta isoform, selective inhibitors are disclosed. The compounds are useful in treating disorders related to abnormal PI3K or PI3K? activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
    Type: Application
    Filed: October 28, 2013
    Publication date: February 20, 2014
    Applicant: Xcovery Holding Company, LLC
    Inventor: Congxin Liang
  • PI3K/mTOR kinase inhibitors
    Patent number: 8586582
    Abstract: 6-morpholin-4-yl-pyrazolo[3,4-d]pyrimidine and 2-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidine derivatives have unexpected drug properties as inhibitors of PI3 and/or mTOR kinases and are useful in treating disorders related to abnormal PI3K/mT0R activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: November 19, 2013
    Assignee: Xcovery Holding Company, LLC
    Inventors: Congxin Liang, Zhigang Li
  • PI3K (delta) selective inhibitors
    Patent number: 8569296
    Abstract: Novel PI3K, especially PI3K delta isoform, selective inhibitors are disclosed. The compounds are useful in treating disorders related to abnormal PI3K or PI3K? activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: October 29, 2013
    Assignee: Xcovery Holding Company, LLC
    Inventor: Congxin Liang
  • INHIBITORS OF FOCAL ADHESION KINASE
    Publication number: 20130281443
    Abstract: The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions.
    Type: Application
    Filed: June 19, 2013
    Publication date: October 24, 2013
    Applicant: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Congxin Liang, Marcel Koenig, Yuanjun He, Par Holmberg
  • Kinase inhibitor compounds
    Patent number: 8551995
    Abstract: Pyridine and pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: October 8, 2013
    Assignee: Xcovery Holding Company, LLC
    Inventor: Congxin Liang
  • Kinase inhibitor compounds
    Patent number: 8524709
    Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: September 3, 2013
    Assignee: Tyrogenex, Inc.
    Inventors: Congxin Liang, Ming Qi, Shu Gao, Zhigang Li
  • PI3K isoform selective inhibitors
    Patent number: 8513221
    Abstract: 2-Morpholin-4-yl-9H-purine and 5-Morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidine derivatives, especially those substituted by 6-heteroaryl, are unexpected PI3 kinase isoform selective inhibitors with good drug properties and are useful in treating disorders related to abnormal PI3K activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: August 20, 2013
    Assignee: Xcovery Holding, LLC
    Inventors: Congxin Liang, Zhigang Li
  • SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS
    Publication number: 20130203763
    Abstract: The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against c-Met and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
    Type: Application
    Filed: October 7, 2011
    Publication date: August 8, 2013
    Applicant: Xcovery Holding Company, LLC
    Inventor: Congxin Liang
  • Inhibitors of focal adhesion kinase
    Patent number: 8501763
    Abstract: The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions.
    Type: Grant
    Filed: March 10, 2008
    Date of Patent: August 6, 2013
    Assignee: The Scripps Research Institute
    Inventors: Congxin Liang, Marcel Koenig, Yuanjun He, Par Holmberg
  • SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS
    Publication number: 20130190298
    Abstract: The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against ALK and are useful in treating disorders related to abnormal protein kinase activities such as cancer, neurological and psychiatric diseases.
    Type: Application
    Filed: October 7, 2011
    Publication date: July 25, 2013
    Applicant: Xcovery Holding Company, LLC.
    Inventor: Congxin Liang
  • mTOR SELECTIVE KINASE INHIBITORS
    Publication number: 20130072481
    Abstract: The 4-urea-phenyl substituted 6-morpholin-4-yl-pyrazolo[3,4-d]pyrimidine derivatives are potent and selective inhibitors of mTOR kinase and are useful in treating disorders related to abnormal mTOR activities such as cancer, immune disorders, cardiovascular disease, ocular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
    Type: Application
    Filed: May 18, 2011
    Publication date: March 21, 2013
    Applicant: XCOVERY HOLDING COMPANY, LLC
    Inventor: Congxin Liang
  • PI3K (delta) SELECTIVE INHIBITORS
    Publication number: 20120202805
    Abstract: Novel PI3K, especially PI3K delta isoform, selective inhibitors are disclosed. The compounds are useful in treating disorders related to abnormal PI3K or PI3K? activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
    Type: Application
    Filed: September 29, 2010
    Publication date: August 9, 2012
    Inventor: Congxin Liang
  • Kinase inhibitor compounds
    Patent number: 8198276
    Abstract: Pyrimidinone derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as inflammatory diseases and certain types of cancer.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: June 12, 2012
    Assignee: Xcovery Holding Company LLC
    Inventor: Congxin Liang
  • KINASE INHIBITOR COMPOUNDS
    Publication number: 20120115866
    Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 10, 2012
    Applicant: TYROGENEX, INC.
    Inventors: Congxin Liang, Ming Qi, Shu Gao, Zhigang Li
  • PI3K/MTOR KINASE INHIBITORS
    Publication number: 20110281857
    Abstract: 6-morpholin-4-yl-pyrazolo[3,4-d]pyrimidine and 2-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidine derivatives have unexpected drug properties as inhibitors of PI3 and/or mTOR kinases and are useful in treating disorders related to abnormal PI3K/mTOR activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
    Type: Application
    Filed: November 11, 2009
    Publication date: November 17, 2011
    Applicant: XCOVERY HOLDING COMPANY, LLC
    Inventors: Congxin Liang, Zhigang Li
  • Kinase inhibitor compounds
    Patent number: 8039470
    Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: October 18, 2011
    Assignee: Tyrogenex, Inc.
    Inventors: Congxin Liang, Ming Qi, Shu Gao, Zhigang Li
  • KINASE INHIBITOR COMPOUNDS
    Publication number: 20110224212
    Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.
    Type: Application
    Filed: May 16, 2011
    Publication date: September 15, 2011
    Applicant: TYROGENEX, INC.
    Inventors: Congxin Liang, Ming Qi, Shu Gao, Zhigang Li